Histone deacetylase inhibitors and neurodegenerative disorders: Holding the promise

Current Pharmaceutical Design

Volumn 15, Issue 34, 2009, Pages 3940-3957

  Mai, Antonello ^a   Rotili, Dante ^a   Valente, Sergio ^a   Kazantsev, Aleksey G ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Epigenetics; Friedreich's ataxia; HDAC inhibitors; Huntington's disease; Neurodegenerative disorders; Parkinson disease; Spinal muscular atrophy

Indexed keywords

4 PHENYLBUTYRIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; BUTYRIC ACID; CARNITINE; ENDURAMIDE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCOSE; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE INHIBITOR; LITHIUM CHLORIDE; LONGEVINEX; MALIC ACID; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NICOTINAMIDE; PLACEBO; QUETIAPINE; RESVERATROL; ROMIDEPSIN; SIRTUIN 1; SIRTUIN 2; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VORINOSTAT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BEHAVIOR DISORDER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; FRIEDREICH ATAXIA; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; METABOLIC DISORDER; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; PSYCHOMOTOR DISORDER; REVIEW; SPINAL MUSCULAR ATROPHY; SPINAL MUSCULAR ATROPHY TYPE 1; SPINAL MUSCULAR ATROPHY TYPE I; SPINAL MUSCULAR ATROPHY TYPE II; SPINAL MUSCULAR ATROPHY TYPE III;

ANIMALS; CELL LINE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MICE; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70649108817     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789649349     Document Type: Review

References (119)

1. Langley B, Gensert JM, Beal MF, Ratan RR. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord 2005; 4(1): 41-50. (Pubitemid 41403313)
2. Saha RN, Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ 2006; 13(4): 539-550
3. Barrett RM, Wood MA. Beyond transcription factors: the role of chromatin modifying enzymes in regulating transcription required for memory. Learn Mem 2008; 15(7): 460-467
4. Hahnen E, Hauke J, Trankle C, Eyupoglu IY, Wirth B, Blumcke I. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin Investig Drugs 2008; 17(2): 169-184 (Pubitemid 351578198)
5. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008; 7(10): 854-868
6. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120.
7. Marmorstein R, Roth SY. Histone acetyltransferases: function, structure, and catalysis. Curr Opin Genet Dev 2001; 11(2): 155-161 (Pubitemid 32209199)
8. Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005; 25(3): 261-309. (Pubitemid 40489663)
9. Grozinger CM, Schreiber SL. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 2002; 9(1): 3-16.
10. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007; 404(1): 1-13. (Pubitemid 46788079)
11. Taylor DM, Maxwell MM, Luthi-Carter R, Kazantsev AG. Biological and potential therapeutic roles of sirtuin deacetylases. Cell Mol Life Sci 2008; 65(24): 4000-4018
12. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5(9): 769-784 (Pubitemid 44348499)
13. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6(1): 38-51. (Pubitemid 43054973)
14. Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009; 41(1): 199-213.
15. Itoh Y, Suzuki T, Miyata N. Isoform-selective histone deacetylase inhibitors. Curr Pharm Des 2008; 14(6): 529-544
16. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008; 409(2): 581-589 (Pubitemid 351184977)
17. Boutillier AL, Trinh E, Loeffler JP. Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J Neurochem 2003; 84(4): 814-828 (Pubitemid 36176939)
18. Rouaux C, Jokic N, Mbebi C, Boutillier S, Loeffler JP, Boutillier AL. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J 2003; 22(24): 6537-6549 (Pubitemid 38009601)
19. Jiang H, Nucifora FC, Jr., Ross CA, DeFranco DB. Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum Mol Genet 2003; 12(1): 1-12.
20. Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, et al. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 2003; 114(5): 635-645 (Pubitemid 37159259)
21. Nucifora FC, Jr., Sasaki M, Peters MF, Huang H, Cooper JK, Yamada M, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001; 291(5512): 2423-2428
22. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425(6954): 191-196 (Pubitemid 37150899)
23. Meisel A, Harms C, Yildirim F, Bosel J, Kronenberg G, Harms U, et al. Inhibition of histone deacetylation protects wild-type but not gelsolin-deficient neurons from oxygen/glucose deprivation. J Neurochem 2006; 98(4): 1019-1031 (Pubitemid 44127779)
24. Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S, et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 2007; 27(13): 3571-3583 (Pubitemid 46515140)
25. Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang CC, et al. Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 2008; 11(8): 1123-1134
26. Sugars KL, Rubinsztein DC. Transcriptional abnormalities in Huntington disease. Trends Genet 2003; 19(5): 233-238
27. Sadri-Vakili G, Cha JH. Mechanisms of disease: Histone modifications in Huntington's disease. Nat Clin Pract Neurol 2006; 2(6): 330-338 (Pubitemid 43811543)
28. Hughes RE, Lo RS, Davis C, Strand AD, Neal CL, Olson JM, et al. Altered transcription in yeast expressing expanded polyglutamine. Proc Natl Acad Sci USA 2001; 98(23): 13201-13206 (Pubitemid 33051340)
29. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001; 413(6857): 739-743 (Pubitemid 33009952)
30. Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, Thompson LM, et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 2008; 17(23): 3767-3775
31. Bates EA, Victor M, Jones AK, Shi Y, Hart AC. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J Neurosci 2006; 26(10): 2830-2838 (Pubitemid 43357867)
32. Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 2005; 37(4): 349-350 (Pubitemid 40490482)
33. McCampbell A, Taye AA, Whitty L, Penney E, Steffan JS, Fischbeck KH. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc Natl Acad Sci USA 2001; 98(26): 15179-15184 (Pubitemid 34013989)
34. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003; 23(28): 9418-9427 (Pubitemid 37323042)
35. Di Rienzo B, Mai A. (Università degli Studi di Roma "La Sapienza", Italy). Preparation of soluble forms of inclusion complexes of histone deacetylase inhibitors and cyclodextrins for use in pharmaceutical compositions. WO Patent 2008-IT40 2008090585.
36. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003; 100(4): 2041-2046 (Pubitemid 36254570)
37. Dokmanovic M, Perez G, Xu W, Ngo L, Clarke C, Parmigiani RB, et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther 2007; 6(9): 2525-2534 (Pubitemid 47480418)
38. Benn CL, Butler R, Mariner L, Nixon J, Moffitt H, Mielcarek M, et al. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. PLoS ONE 2009; 4(6): e5747.
39. Simonini MV, Camargo LM, Dong E, Maloku E, Veldic M, Costa E, et al. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci USA 2006; 103(5): 1587-1592 (Pubitemid 43191209)
40. Wong JC, Hong R, Schreiber SL. Structural biasing elements for in-cell histone deacetylase paralog selectivity. J Am Chem Soc 2003; 125(19): 5586-5587
41. Mai A, Perrone A, Nebbioso A, Rotili D, Valente S, Tardugno M, et al. Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities. Bioorg Med Chem Lett 2008; 18(8): 2530-2535
42. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003; 46(24): 5097-5116
43. Mai A, Massa S, Rotili D, Pezzi R, Bottoni P, Scatena R, et al. Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. Bioorg Med Chem Lett 2005; 15(21): 4656-4661 (Pubitemid 41354786)
44. Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R, et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA 2008; 105(40): 15564-15569
45. Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, et al. Neuroprotective effects of phenylbutyrate in the N171- 82Q transgenic mouse model of Huntington's disease. J Biol Chem 2005; 280(1): 556-563 (Pubitemid 40165021)
46. Southwood CM, Peppi M, Dryden S, Tainsky MA, Gow A. Microtubule deacetylases, SirT2 and HDAC6, in the nervous system. Neurochem Res 2007; 32(2): 187-195 (Pubitemid 46238864)
47. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007; 447(7146): 859-863 (Pubitemid 46920134)
48. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388(6645): 839-840
49. Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol 1998; 57(4): 334-337 (Pubitemid 28182631)
50. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115(6): 727-738 (Pubitemid 38030301)
51. Takahashi-Fujigasaki J, Fujigasaki H. Histone deacetylase (HDAC) 4 involvement in both Lewy and Marinesco bodies. Neuropathol Appl Neurobiol 2006; 32(5): 562-566 (Pubitemid 44401518)
52. Kontopoulos E, Parvin JD, Feany MB. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 2006; 15(20): 3012-3023 (Pubitemid 44530705)
53. Leng Y, Chuang DM. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 2006; 26(28): 7502-7512 (Pubitemid 44315219)
54. Gardian G, Yang L, Cleren C, Calingasan NY, Klivenyi P, Beal MF. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromol Med 2004; 5(3): 235-241 (Pubitemid 40125304)
55. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006; 11(12): 1116-1125 (Pubitemid 44867481)
56. van Ham TJ, Thijssen KL, Breitling R, Hofstra RM, Plasterk RH, Nollen EA. C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet 2008; 4(3): e1000027.
57. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007; 317(5837): 516-519 (Pubitemid 47196116)
58. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 2004; 279(6): 4625-4631
59. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science 2006; 313(5793): 1604-1610 (Pubitemid 44414028)
60. Jensen PH, Islam K, Kenney J, Nielsen MS, Power J, Gai WP. Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments. J Biol Chem 2000; 275(28): 21500-21507 (Pubitemid 30481854)
61. Alim MA, Ma QL, Takeda K, Aizawa T, Matsubara M, Nakamura M, et al. Demonstration of a role for alpha-synuclein as a functional microtubule- associated protein. J Alzheimers Dis 2004; 6(4): 435-42; discussion 43-49
62. Outeiro TF, Marques O, Kazantsev A. Therapeutic role of sirtuins in neurodegenerative disease. Biochim Biophys Acta 2008; 1782(6): 363-369
63. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006; 314(5800): 777-781
64. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005; 37(2): 289-305.
65. Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005; 76(2): 77-98.
66. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007; 26(13): 3169-3179 (Pubitemid 47057498)
67. Anekonda TS, Reddy PH. Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem 2006; 96(2): 305-313
68. Gan L, Mucke L. Paths of convergence: sirtuins in aging and neurodegeneration. Neuron 2008; 58(1): 10-14
69. Qin W, Chachich M, Lane M, Roth G, Bryant M, de Cabo R, et al. Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus). J Alzheimers Dis 2006; 10(4): 417-422 (Pubitemid 46252805)
70. Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 2006; 281(31): 21745-21754 (Pubitemid 44181878)
71. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005; 280(45): 37377-37382 (Pubitemid 41642343)
72. Julien C, Tremblay C, Emond V, Lebbadi M, Salem N, Jr., Bennett DA, et al. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 2009; 68(1): 48-58.
73. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23(12): 2369-2380 (Pubitemid 38954844)
74. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005; 280(48): 40364-40374 (Pubitemid 41779174)
75. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 2007; 28(1): 91-106. (Pubitemid 47531974)
76. Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci 2008; 28(45): 11500-11510
77. Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005; 93(5): 1087-1098 (Pubitemid 40776564)
78. Sugai F, Yamamoto Y, Miyaguchi K, Zhou Z, Sumi H, Hamasaki T, et al. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 2004; 20(11): 3179-3183 (Pubitemid 40007312)
79. Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 2008; 155(3): 567-572
80. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 2008; 28(10): 2576-2588
81. Cohen TJ, Barrientos T, Hartman ZC, Garvey SM, Cox GA, Yao TP. The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity. FASEB J 2009; 23(1): 99-106.
82. Cohen TJ, Waddell DS, Barrientos T, Lu Z, Feng G, Cox GA, et al. The histone deacetylase HDAC4 connects neural activity to muscle transcriptional reprogramming. J Biol Chem 2007; 282(46): 33752-33759 (Pubitemid 350159508)
83. Wirth B, Brichta L, Hahnen E. Spinal muscular atrophy: from gene to therapy. Semin Pediatr Neurol 2006; 13(2): 121-131 (Pubitemid 44486827)
84. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001; 98(17): 9808-9813 (Pubitemid 32769385)
85. Andreassi C, Angelozzi C, Tiziano FD, Vitali T, De Vincenzi E, Boninsegna A, et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004; 12(1): 59-65.
86. Sumner CJ, Huynh TN, Markowitz JA, Perhac JS, Hill B, Coovert DD, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003; 54(5): 647-654 (Pubitemid 37346071)
87. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003; 12(19): 2481-2489 (Pubitemid 37220412)
88. Hahnen E, Eyupoglu IY, Brichta L, Haastert K, Trankle C, Siebzehnrubl FA, et al. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 2006; 98(1): 193-202.
89. Hauke J, Riessland M, Lunke S, Eyupoglu IY, Blumcke I, El-Osta A, et al. Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum Mol Genet 2009; 18(2): 304-317
90. Kernochan LE, Russo ML, Woodling NS, Huynh TN, Avila AM, Fischbeck KH, et al. The role of histone acetylation in SMN gene expression. Hum Mol Genet 2005; 14(9): 1171-1182 (Pubitemid 40613906)
91. Tsai LK, Tsai MS, Lin TB, Hwu WL, Li H. Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol Dis 2006; 24(2): 286-295 (Pubitemid 44572748)
92. Avila AM, Burnett BG, Taye AA, Gabanella F, Knight MA, Hartenstein P, et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 2007; 117(3): 659-671 (Pubitemid 46348524)
93. Mercuri E, Bertini E, Messina S, Pelliccioni M, D'Amico A, Colitto F, et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 2004; 14(2): 130-135 (Pubitemid 38083321)
94. Brahe C, Vitali T, Tiziano FD, Angelozzi C, Pinto AM, Borgo F, et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 2005; 13(2): 256-259 (Pubitemid 40220572)
95. Brichta L, Holker I, Haug K, Klockgether T, Wirth B. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol 2006; 59(6): 970-975
96. Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 2006; 67(3): 500-501 (Pubitemid 44214981)
97. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007; 321(3): 892-901. (Pubitemid 46762687)
98. Faraco G, Pancani T, Formentini L, Mascagni P, Fossati G, Leoni F, et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 2006; 70(6): 1876-1884 (Pubitemid 44771903)
99. Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T, et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J 2008; 22(10): 3549-3560
100. Liu D, Gharavi R, Pitta M, Gleichmann M, Mattson MP. Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons. Neuromol Med 2009; 11(1): 28-42.
101. Della-Morte D, Dave KR, DeFazio RA, Bao YC, Raval AP, Perez-Pinzon MA. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience 2009; 159(3): 993-1002.
102. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006; 2(10): 551-558 (Pubitemid 44413238)
103. Chou CJ, Herman D, Gottesfeld JM. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem 2008; 283(51): 35402-35409
104. Rai M, Soragni E, Jenssen K, Burnett R, Herman D, Coppola G, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 2008; 3(4): e1958.
105. Kim D, Frank CL, Dobbin MM, Tsunemoto RK, Tu W, Peng PL, et al. Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron 2008; 60(5): 803-817
106. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009; 459(7243): 55-60.
107. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009; 15(1): 91-99
108. Bolger TA, Zhao X, Cohen TJ, Tsai CC, Yao TP. The neurodegenerative disease protein ataxin-1 antagonizes the neuronal survival function of myocyte enhancer factor-2. J Biol Chem 2007; 282(40): 29186-29192
109. Chen B, Cepko CL. HDAC4 regulates neuronal survival in normal and diseased retinas. Science 2009; 323(5911): 256-259
110. Renthal W, Maze I, Krishnan V, Covington HE, 3rd, Xiao G, Kumar A, et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 2007; 56(3): 517-529 (Pubitemid 350030878)
111. Mejat A, Ramond F, Bassel-Duby R, Khochbin S, Olson EN, Schaeffer L. Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation and gene expression. Nat Neurosci 2005; 8(3): 313-321 (Pubitemid 40300188)
112. Liu H, Hu Q, Kaufman A, D'Ercole AJ, Ye P. Developmental expression of histone deacetylase 11 in the murine brain. J Neurosci Res 2008; 86(3): 537-543 (Pubitemid 351204467)
113. Kim MJ, Ahn K, Park SH, Kang HJ, Jang BG, Oh SJ, et al. SIRT1 regulates tyrosine hydroxylase expression and differentiation of neuroblastoma cells via FOXO3a. FEBS Lett 2009; 583(7): 1183-1188
114. Tang BL, Chua CE. SIRT2, tubulin deacetylation, and oligodendroglia differentiation. Cell Motil Cytoskeleton 2008; 65(3): 179-182
115. Suzuki K, Koike T. Mammalian Sir2-related protein (SIRT) 2-mediated modulation of resistance to axonal degeneration in slow Wallerian degeneration mice: a crucial role of tubulin deacetylation. Neuroscience 2007; 147(3): 599-612. (Pubitemid 46990654)
116. Pfister JA, Ma C, Morrison BE, D'Mello SR. Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS ONE 2008; 3(12): e4090.
117. Choo QY, Ho PC, Lin HS. Histone deacetylase inhibitors: new hope for rheumatoid arthritis? Curr Pharm Des 2008; 14(8): 803-820
118. Hadjipavlou-Litina D. Histone deacetylase inhibitors. Curr Pharm Des 2008; 14(6): 504.
119. Neugebauer RC, Sippl W, Jung M. Inhibitors of NAD+ dependent histone deacetylases (sirtuins). Curr Pharm Des 2008; 14(6): 562-573